NASDAQ · NYXH
Healthcare · Medical - Instruments & Supplies
$1.42
Down-$0.07 (-4.93%)
Updated Oct 8, 2026, 11:29 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · NYXH
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
NYXH closed at $1.42 after 21 trading sessions, down 6.58% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $1.42 | $1.45 | $1.41 | $1.42 | 81.49K |
| Oct 6, 2026 | $1.43 | $1.47 | $1.40 | $1.43 | 132.5K |
| Oct 5, 2026 | $1.37 | $1.465 | $1.36 | $1.41 | 191.98K |
| Oct 2, 2026 | $1.34 | $1.36 | $1.32 | $1.36 | 68.55K |
| Oct 1, 2026 | $1.38 | $1.38 | $1.31 | $1.33 | 120.79K |
| Sep 30, 2026 | $1.40 | $1.41 | $1.36 | $1.38 | 189.88K |
| Sep 29, 2026 | $1.51 | $1.51 | $1.37 | $1.37 | 337.35K |
| Sep 28, 2026 | $1.605 | $1.6699 | $1.555 | $1.59 | 642.58K |
| Sep 25, 2026 | $1.34 | $1.47 | $1.34 | $1.45 | 264.06K |
| Sep 24, 2026 | $1.30 | $1.32 | $1.27 | $1.27 | 183.88K |
| Sep 23, 2026 | $1.40 | $1.405 | $1.30 | $1.33 | 257.78K |
| Sep 22, 2026 | $1.46 | $1.46 | $1.39 | $1.40 | 149.13K |
| Sep 21, 2026 | $1.50 | $1.50 | $1.46 | $1.48 | 59.76K |
| Sep 18, 2026 | $1.50 | $1.51 | $1.47 | $1.48 | 81.03K |
| Sep 17, 2026 | $1.56 | $1.56 | $1.4801 | $1.49 | 74.4K |
| Sep 16, 2026 | $1.56 | $1.58 | $1.5301 | $1.55 | 153.45K |
| Sep 15, 2026 | $1.58 | $1.58 | $1.53 | $1.54 | 64.33K |
| Sep 14, 2026 | $1.55 | $1.62 | $1.54 | $1.60 | 154.44K |
| Sep 11, 2026 | $1.54 | $1.57 | $1.51 | $1.54 | 179.48K |
| Sep 10, 2026 | $1.51 | $1.525 | $1.47 | $1.50 | 188.24K |
| Sep 9, 2026 | $1.56 | $1.56 | $1.505 | $1.52 | 237.86K |
The latest Smart Investors Daily articles mentioning NYXH.
Company
Market Activity
Research & News
NYXH research
Company profile and research snapshot.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 16, 2026 | CANTOR FITZGERALD | Overweight | — |
| Sep 3, 2026 | DEGROOF PETERCAM | Buy | — |
| Aug 17, 2026 | STIFEL EUROPE | Hold | — |
| Aug 6, 2026 | OPPENHEIMER & CO., INC. | Outperform | — |
| Aug 6, 2026 | PIPER SANDLER COMPANIES | Overweight | — |
No generated briefing is available yet.
Yahoo · Oct 6, 2026
Schrodinger (SDGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
SeekingAlpha · Oct 5, 2026
Nyxoah (NYXH) outlook: Genio OSA implant growth, FDA label catalyst & 2026 revenue ramp.
Yahoo · Sep 28, 2026
REGULATED INFORMATIONINSIDE INFORMATION Nyxoah Appoints Liam Kelly as Chief Executive Officer Further strengthening the Company’s strategic U.S. presence and focus Mont-Saint-Guibert, Belgium – September 28, 2026, 10:30 pm CET / 4:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of Liam Kelly as
Yahoo · Sep 23, 2026
Landry joins in the aftermath of an investor’s call for the sale of the heart failure device company.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NYXH.
